Revance Therapeutics 2024 JP Morgan Healthcare Conference

Loading viewer...

conference

Format: PDF conference

Revance Therapeutics presented its 2024 strategic priorities and commercial update at the JP Morgan Healthcare Conference, focusing on DAXXIFY® expansion into therapeutics including cervical dystonia, RHA® dermal fillers pipeline growth, and path to positive adjusted EBITDA. The presentation covers commercialization strategy, market opportunities, and financial guidance for 2024.

Browse all conferences →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Revance Therapeutics

View all →

Revance Aesthetics Portfolio TEOXANE Dermal Fillers 2020

investor_presentation

25 Pages

Revance Therapeutics Investor Presentation — April 2018

investor_presentation

Similar conferences from other companies

Browse all →

Xcel Energy 2016 Wells Fargo Utility Symposium

conference

44 Pages

Xcel Energy

Intercontinental Exchange ICE 2016 Conference Presentation

conference